The insider selling is too small to warrant a bearish read. Routine derivative exercises and sales by a CMO and director are common for liquidity and tax planning. Monitor for any upcoming clinical catalysts or earnings news that could provide context, but no immediate action is required.
IMNM drugs
IMNM drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 8 $24.01entry
- T+1 · 4mo ago +0.67%α −0.18% · $24.17
- T+5 · 4mo ago −5.91%α −6.78% · $22.59
- T+20 · 3mo ago +6.29%α +3.02% · $25.52
- T+60 · 7w ago −12.99%α −15.49% · $20.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Immunome (CMO and a director) sold shares totaling $2.19M in open-market transactions over a 7-day window. The sales represent less than 0.1% of the company's $2.7B market cap, making them routine and non-material. No specific catalyst or pattern suggests informed selling.
Key Financial Metrics
Key Facts
- Total open-market sales of $2.19M by two insiders (CMO Robert Lechleider and Director Isaac Barchas) over a 7-day window ending July 2, 2026.
- Sales represent approximately 0.08% of Immunome's $2.7B market cap, well below the 0.1% materiality threshold.
- CMO Lechleider also exercised 110,000 stock options (55,000 at $0 and 55,000 at $8.73) concurrently with the sales, a common pattern to cover tax obligations or generate liquidity.
Financial Impact
Negligible, less than 0.1% of market cap sold.
Risk Factors
- Insider selling could continue if the stock price appreciates further, but the current level is immaterial.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-IMNM-1783461710403 |
Track record
20 reports on IMNM
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +26.53% at T+60 after the May 28, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $18.39 Now $17.61 −4.24% settles Feb 12
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago S-3ASR Neutral 3/10 Entry $18.65 Now $17.61 −5.58% settles Feb 8
- Nov 9, 20267d ago 8-K Bearish 5/10 Entry $18.65 Now $17.61 +5.58% settles Feb 8
- Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $18.21 Now $17.61 −3.29% settles Jan 28
- Oct 16, 20264w ago ANALYST-UPGRADE Bullish 4/10 Entry $16.47 Now $17.61 +6.92% settles Jan 13
- Oct 5, 20266w ago 8-K Bullish 6/10 Entry $21.17 Now $17.61 −16.82% settles Dec 30
- Oct 1, 20266w ago ANALYST-UPGRADE Bearish 4/10 Entry $20.89 Now $17.61 +15.70% settles Dec 28
- Sep 21, 20268w ago ANALYST-UPGRADE Bullish 4/10 Entry $25.07 Now $17.61 −29.76% settles Dec 15
- Aug 12, 202613w ago Insider Cluster Neutral 4/10 Entry $26.42 to $18.71 Now $17.61 −33.35% ▼ −29.18% −23.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers